This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (110)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Sue J. Goldie, MD, MPH; Karen M. Kuntz, ScD; Milton C. Weinstein, PhD; Kenneth A. Freedberg, MD, MSc; Mark L. Welton, MD; Joel M. Palefsky, MD

JAMA. 1999;281:1822-1829.

Context  Homosexual and bisexual men infected with human immunodeficiency virus (HIV) are at increased risk for human papillomavirus–related anal neoplasia and anal squamous cell carcinoma (SCC).

Objective  To estimate the clinical benefits and cost-effectiveness of screening HIV-positive homosexual and bisexual men for anal squamous intraepithelial lesions (ASIL) and anal SCC.

Design  Cost-effectiveness analysis performed from a societal perspective that used reference case recommendations from the Panel on Cost-Effectiveness in Health and Medicine. A state-transition Markov model was developed to calculate lifetime costs, life expectancy, and quality-adjusted life expectancy for no screening vs several screening strategies for ASIL and anal SCC using anal Papanicolaou (Pap) testing at different intervals. Values for incidence, progression, and regression of anal neoplasia; efficacy of screening and treatment; natural history of HIV; health-related quality of life; and costs were obtained from the literature.

Setting and Participants  Hypothetical cohort of homosexual and bisexual HIV-positive men living in the United States.

Main Outcome Measures  Life expectancy, quality-adjusted life expectancy, quality-adjusted years of life saved, lifetime costs, and incremental cost-effectiveness ratio.

Results  Screening for ASIL increased quality-adjusted life expectancy at all stages of HIV disease. Screening with anal Pap tests every 2 years, beginning in early HIV disease (CD4 cell count >0.50x10⁹/L), resulted in a 2.7-month gain in quality-adjusted life expectancy for an incremental cost-effectiveness ratio of $13,000 per quality-adjusted life year saved. Screening with anal Pap tests yearly provided additional benefit at an incremental cost of $16,600 per quality-adjusted life year saved. If screening was not initiated until later in the course of HIV disease (CD4 cell count <0.50x10⁹/L), then yearly Pap test screening was preferred due to the greater amount of prevalent anal disease (cost-effectiveness ratio of less than $25,000 per quality-adjusted life year saved compared with no screening). Screening every 6 months provided little additional benefit over that of yearly screening. Results were most sensitive to the rate of progression of ASIL to anal SCC and the effectiveness of treatment of precancerous lesions.

Conclusions  Screening HIV-positive homosexual and bisexual men for ASIL and anal SCC with anal Pap tests offers quality-adjusted life expectancy benefits at a cost comparable with other accepted clinical preventive interventions.

Author Affiliations: Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass (Drs Goldie, Kuntz, and Weinstein); the Clinical Economics Research Unit, Section of General Internal Medicine and Clinical AIDS Program, Department of Medicine and Evans Medical Foundation, Boston Medical Center, Department of Epidemiology and Biostatistics, Schools of Medicine and Public Health, Boston University, Boston, Mass (Dr Freedberg); and Departments of Surgery (Dr Welton) and Laboratory Medicine and Medicine (Dr Palefsky), University of California, San Francisco.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

May 19, 1999
JAMA. 1999;281(19):1863-1864.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

AIDS-Related Malignancies: State of the Art and Therapeutic Challenges
Spano et al.
JCO 2008;26:4834-4842.
ABSTRACT | FULL TEXT  

Improved Screening for Anal Neoplasia by Immunocytochemical Detection of Minichromosome Maintenance Proteins
Scarpini et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2855-2864.
ABSTRACT | FULL TEXT  

Cost-utility analysis of screening high-risk groups for anal cancer
Karnon et al.
J Public Health (Oxf) 2008;30:293-304.
ABSTRACT | FULL TEXT  

Squamous Cell Carcinoma of the Anal Canal: Utilization and Outcomes of Recommended Treatment in the United States
Bilimoria et al.
Ann. Surg. Oncol. 2008;15:1948-1958.
ABSTRACT | FULL TEXT  

Treatment of anal human papillomavirus-associated disease: a long term outcome study
Nathan et al.
Int J STD AIDS 2008;19:445-449.
ABSTRACT | FULL TEXT  

High-Resolution Anoscopy in the Diagnosis of Anal Cancer Precursor Lesions in Renal Graft Recipients
da Costa e Silva et al.
Ann. Surg. Oncol. 2008;15:1470-1475.
ABSTRACT | FULL TEXT  

A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
Hornberger et al.
Med Decis Making 2007;27:789-821.
ABSTRACT  

Human Papillomavirus Infections in Primary Care
Ogunmodede et al.
Clin Med Res 2007;5:210-217.
ABSTRACT | FULL TEXT  

Anal Cancer: An Overview
Uronis and Bendell
The Oncologist 2007;12:524-534.
ABSTRACT | FULL TEXT  

Anal Cancer in HIV Infection: To Screen or Not to Screen?
AIDS Clin Care 2004;2004:1-1.
FULL TEXT  

Cost-Utility Analysis of Preoperative Radiotherapy in Patients With Rectal Cancer Undergoing Total Mesorectal Excision: A Study of the Dutch Colorectal Cancer Group
van den Brink et al.
JCO 2004;22:244-253.
ABSTRACT | FULL TEXT  

Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS
Mrus et al.
Med Decis Making 2003;23:414-421.
ABSTRACT  

Chapter 15: Public Health Policy and Cost-Effectiveness Analysis
Goldie
J Natl Cancer Inst Monogr 2003;2003:102-110.
ABSTRACT | FULL TEXT  

A Potential Error in Evaluating Cancer Screening: A Comparison of 2 Approaches for Modeling Underlying Disease Progression
Goldie and Kuntz
Med Decis Making 2003;23:232-241.
ABSTRACT  

High Prevalence of Anal Human Papillomavirus Infection and Anal Cancer Precursors among HIV-Infected Persons in the Absence of Anal Intercourse
Piketty et al.
ANN INTERN MED 2003;138:453-459.
ABSTRACT | FULL TEXT  

Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America
Masur et al.
ANN INTERN MED 2002;137:435-478.
ABSTRACT | FULL TEXT  

U.S. Centers for Disease Control and Prevention Guidelines for the Treatment of Sexually Transmitted Diseases: An Opportunity To Unify Clinical and Public Health Practice
Workowski et al.
ANN INTERN MED 2002;137:255-262.
ABSTRACT | FULL TEXT  

Carcinoma of the Anus: Strategies in Management
Esiashvili et al.
The Oncologist 2002;7:188-199.
ABSTRACT | FULL TEXT  

Encapsulated Plasmid DNA Treatment for Human Papillomavirus 16-associated Anal Dysplasia: A Phase I Study of ZYC101
Klencke et al.
Clin. Cancer Res. 2002;8:1028-1037.
ABSTRACT | FULL TEXT  

Anal intraepithelial neoplasia in HIV positive people
Martin and Bower
Sex. Transm. Infect. 2001;77:327-331.
ABSTRACT | FULL TEXT  

Prevalence and Risk Factors for Anal Squamous Intraepithelial Lesions in Women
Holly et al.
JNCI J Natl Cancer Inst 2001;93:843-849.
ABSTRACT | FULL TEXT  

Carcinoma of the Anal Canal
Ryan et al.
NEJM 2000;342:792-800.
FULL TEXT  

1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus
USPHS/IDSA Prevention of Opportunistic Infections
ANN INTERN MED 1999;131:873-908.
FULL TEXT  

Screening for Anal Carcinoma
AIDS Clin Care 1999;1999:6-6.
FULL TEXT